Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Temps réel estimé Cboe Europe Autres places de cotation 16:16:52 11/05/2026			Varia. 5j.	Varia. 1 janv.
13 576,00 ^GBX	+1,74%		+2,12%	-1,29%

07/05	Fluicell propose une dirigeante d'AstraZeneca pour siéger à son conseil d'administration	FW
07/05	Actions nordiques en Amérique du Nord - Autoliv recule de 0,6 pour cent	FW

Communiqués

07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
03/05	AstraZeneca invests £300 million in UK drug development sites	AQ
01/05	TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
01/05	AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
30/04	AstraZeneca : Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer	PU
30/04	Astrazeneca injects £300m into UK sites	AQ
30/04	Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca	PR
29/04	Astrazeneca tops expectations in the first quarter on strong cancer drug sales	AQ
29/04	AstraZeneca results: Q1 2026	BU
29/04	AstraZeneca : Q1 2026 results clinical trials appendix (Q1 2026 results clinical trials appendix)	PU
29/04	Astrazeneca: Q1 Earnings Snapshot	AQ
28/04	BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older	BU
27/04	SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus	BU
20/04	Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD	BU
20/04	AstraZeneca : Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD	PU
09/04	AstraZeneca : Special Business Approved at AGM	PU
09/04	AstraZeneca : Results of Annual General Meeting held on 9 April 2026 (Results of Annual General Meeting held on 9 April 2026)	PU
08/04	AstraZeneca : Sustainability Data Reporting Criteria 2025	PU
08/04	AstraZeneca : Assurance Report for Sustainability Data Annex 2025	PU
08/04	AstraZeneca : Sustainability Data Annex 2025	PU
02/04	IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer	BU
02/04	AstraZeneca : Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial	PU